PALISADE BIO INC(NASDAQ:PALI) stock News

PALI Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Chartmill - Mentions: INTC NVDA OPEN BTBT ...

Curious about the most active stocks on Thursday?

a day ago - By: Palisade Bio, Inc.

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

15 days ago - By: Benzinga - Mentions: EQ AZTR FGEN MYO ...

12 Health Care Stocks Moving In Monday's After-Market Session

19 days ago - By: Palisade Bio, Inc.

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

a month ago - By: Palisade Bio, Inc.

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

a month ago - By: Palisade Bio, Inc.

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

a month ago - By: Palisade Bio, Inc.

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

a month ago - By: ACCESS Newswire - Mentions: AKTX AMIX CNSP NVNO ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

4 months ago - By: Palisade Bio, Inc.

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

5 months ago - By: Palisade Bio, Inc.

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

6 months ago - By: Palisade Bio, Inc.

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

6 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

6 months ago - By: Palisade Bio, Inc.

Palisade Bio Participates in Virtual Investor “What This Means” Segment

6 months ago - By: Palisade Bio, Inc.

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

7 months ago - By: Palisade Bio, Inc.

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

7 months ago - By: Palisade Bio, Inc.

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

7 months ago - By: Palisade Bio, Inc.

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

9 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

9 months ago - By: Benzinga

What's Going On With Palisade Bio Stock On Thursday?

9 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

9 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

9 months ago - By: Palisade Bio, Inc.

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

PALISADE BIO INC (PALI) Stock News

PALI Latest News, Press Relases and Analysis